Implantica (IMP-A-SDB.ST) Stock Analysis & AI Equity Report
Implantica (IMP-A-SDB.ST) overview
Implantica (IMP-A-SDB.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Implantica reported revenue of EUR 2.1m and operating profit of EUR -19.6m; the year-end share price was 50.10 SEK and market capitalisation was SEK 3,481m. Implantica is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Implantica's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-21. Data will be refreshed during report generation.
About Implantica
Implantica AG is a medtech company developing implantable technologies and products for gastrointestinal and other conditions. Its lead product is RefluxStop, a CE-marked implant for gastroesophageal reflux disease. The company also is developing eHealth and wireless energizing platforms and a broader pipeline of smart medical implants.
Generate the Implantica report
Implantica is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Implantica and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.